CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI) Ticagrelor with or without Aspirin in High-Risk Patients after PCI Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial
|<<... 7 8 9 10 11 12 13 ...>>|

JOURNAL：CBS2017 Article Link

Make a Voice to the World

CBS2017


Denver - October 29, from 11 to 11:30 a.m., Dr Peter Block gave Prof Shao-Liang Chen from Nanjing First Hospital an in-depth interview in the Colorado Convention Center at TCT2017 (Transcatheter Cardiovascular Therapy conference). Prof Shao-Liang Chen is the initiator of DK Crush-V, which using randomized, prospective, multinational design to evaluate the efficacy and safety of DK crush over provisional side branch stenting for patients with unprotected left main bifurcation lesions.


With the further development of interventional devices , coronary bifurcation lesions remains as the one of the most challenging cardiovascular diseases to be tackled. Varies of treatment strategies need high reliability, high level of evidence before promoted in global clinical practices. With passion and faith for better clinical outcome, Prof Chen and his research team keep working on this issue over ten years, seeking a better treatment strategy  for unprotected left main bifurcation lesions. This time, he share his professional clinical experiences and perspectives with international colleagues about the "Current practice and perspectives on treatment in left main bifurcation in China" at TCT2017.






As the leading event in the fields of left main coronary artery disease and transcatheter valve disease, this year, TCT2017 presents 12 LBCTs and 16 FRIs to cause attention.  The progress of DK-V is one of the most notable results, which will be released on October 30th at 11:40 am, local time (at 1:40 a.m. on November 1, Beijing time).



Important Events at TCT2017





>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top